Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Merenkova (Kiev, Ukraine), Y. Dziublyk (Kiev, Ukraine), G. Gumeniuk (Kiev, Ukraine), M. Gumeniuk (Kiev, Ukraine). Glucocorticosteroid therapy as predisposing factor for pulmonary sarcoidosis relapse. 3006

Member's Comments

No comment yet.

Related content which might interest you: Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 The assessment of risk factors and treatment of pulmonary TB relapses Source: Eur Respir J 2006; 28: Suppl. 50, 129s Year: 2006 Type of anticoagulant therapy as a risk factor for the severity of chronic thromboembolic pulmonary hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Risk factors for recurrences in patients with idiopathic pulmonary embolism after withdrawal of long-term anticoagulation Source: Eur Respir J 2006; 28: Suppl. 50, 44s Year: 2006 Eosinopenia as a prognostic factor in patients with acute exacerbation of chronic obstructive pulmonary disease. Source: International Congress 2017 – COPD and weaning Year: 2017 Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1701197; 10.1183/13993003.01197-2017 Year: 2018 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Prognostic factors in non-surgical chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor? Source: Eur Respir Rev 2011; 20: 210-212 Year: 2011 Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome Source: Eur Respir J 2011; 37: 356 Year: 2011 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Prognostic factors in surgically-treated chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 4 (1) 00111-2016; 10.1183/23120541.00111-2016 Year: 2018 Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006 Thrombophilia in patients with idiopathic pulmonary thromboembolism vs associated with risk factors Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008